Sabby group reports 9.87% Lyra Therapeutics (LYRA) ownership stake
Rhea-AI Filing Summary
Lyra Therapeutics, Inc. received a Schedule 13G filing showing that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together report beneficial ownership of 175,158 shares of Lyra common stock. This position represents 9.87% of the outstanding common shares as of the event date. The filing states that all three reporting persons share both voting and dispositive power over these shares and have no sole voting or dispositive authority.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Lyra Therapeutics, describing the position as a passive investment under Schedule 13G.
Positive
- None.
Negative
- None.
Insights
A Sabby-affiliated group reports a passive 9.87% stake in Lyra.
The filing shows that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively report beneficial ownership of 175,158 Lyra Therapeutics common shares, equal to 9.87% of the class. Voting and dispositive power over these shares is shared among the reporting persons, with no sole authority reported.
The use of a Schedule 13G and the certification language indicate the position is being reported as a passive investment rather than an attempt to influence control. Future ownership updates, if any, would typically appear in subsequent beneficial ownership filings when thresholds or positions change.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Who filed the Schedule 13G for Lyra Therapeutics (LYRA)?
The Schedule 13G for Lyra Therapeutics, Inc. was filed by Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz as the reporting persons.
What percentage of Lyra Therapeutics common stock does the Sabby group own?
The Schedule 13G states that Sabby Volatility Warrant Master Fund, Sabby Management, and Hal Mintz each report 9.87% beneficial ownership of Lyra Therapeutics outstanding common stock.
Is the Sabby position in Lyra Therapeutics reported as passive or active?
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Lyra Therapeutics, indicating a passive investment under Schedule 13G.
What is the event date for the Lyra Therapeutics Schedule 13G holding?
The date of the event that triggered this Schedule 13G filing is December 31, 2025, as listed in the document.